Marco Meglio

Rozanolixizumab was associated with reductions in anti-acetylcholine receptor autoantibodies and was well tolerated across 2 dose levels with no new safety findings.

Michael Okun, MD, executive director of the Norman Fixel Institute for Neurological Diseases sat down to discuss his viewpoint paper on changing the approval system for neurotechnological devices in rare diseases.

Evidence from 2 clinical trials were the basis of the biologics license application, with an FDA decision expected to be made by May 18, 2021.

An overview of the NeurologyLive tweet chat honoring National Epilepsy Awareness Month, featuring highlighted contributions from the medical community.

The GABAergic mechanism of sodium oxybate was able to increase simple movements in non-rapid eye movement sleep.

The vice president of Clinical Research at Eisai provides updates on the MOMENTUM trials which will examine lorcaserin as a potential treatment for patients with Dravet syndrome.

Frailty index score can identify patients at risk for cognitive dysfunction and might be an important marker with potential prognostic value.

The first trial of tranexamic acid in patients with known ongoing intracerebral hemorrhage shows insignificance compared with placebo, with future studies of simpler recruitment methods needed.

Women who did not work for pay post-childbearing represented the greatest later-life cognitive decline population in the first ever study that evaluated influence of work-family profiles.

COVID-19 positive patients with Guillain-Barre syndrome were predominately of demyelinating subtype and appeared more severe than non-COVID-19 patients with Guillain-Barré syndrome.

A net benefit was observed for all functional outcomes across the entire range of the modified Rankin Scale despite an increased risk of symptomatic intracranial hemorrhage.

The study authors noted that dementia prevention could become a compelling indication for older individuals receiving antihypertensive treatment.

The chief scientific officer of the Parkinson’s Foundation discussed how the PD GENEration initiative tackles 1 of the greatest unmet needs for patients with Parkinson disease.

Veronica Hood, PhD, of the Dravet Syndrome Foundation, details the recently accepted ICD-10 codes for Dravet syndrome and what benefit they bring to patients.

New recommendations were developed for the use of rituximab, eculizumab, and methotrexate, as well as updates on previous recommendations for thymectomy.

The decision was based on findings from the phase 3 THALES trial, which showed aspirin plus ticagrelor significantly reduced stroke and death compared with aspirin alone in patients with acute ischemic stroke or TIA.

Based on data from a study of 686 patients with subjective cognitive impairment or dementia, the PrecivityAD blood test correctly identified brain amyloid plaque status in 86% of the patients.

The new codes have broader implications in helping clinicians understand the morbidity and mortality related to the disorder.

Joe Verghese, MBBS, MS, details the research being conducted on motoric cognitive risk syndrome and noninvasive brain stimulation in Alzheimer disease.

Findings from PD GENEration will contribute to the biological understanding of the disease and help researchers assess the impact of each mutation.

The percent change from baseline was lower in those who initiated ocrelizumab early than those initially on placebo for both T2 lesion volume and T1 hypointense lesion volume.

The findings suggest that poor speech-in-noise hearing may be an early marker of underlying dementia processes.

Anup Patel, MD, section chief of pediatric neurology at Nationwide Children’s Hospital, explained how care for patients with Lennox-Gastaut syndrome has changed throughout the pandemic.

The researchers concluded that the effect of lowered blood pressure might not be evident in specific domains of cognitive function, but instead distributed across multiple domains.

The company is planning a pivotal trial of blarcamesine in Parkinson disease dementia after submitting results of the phase 2 study to the FDA for regulatory guidance.

In part 2 of this interview, Elias Kouchakji, MD, gives perspective on pamrevlumab’s unique pathway as a Duchenne muscular dystrophy treatment nearing the end of the clinical pipeline.

The authors noted that research is still needed to establish standards for cell mobilization and immune-conditioning regimens.

The professor of neurology at the NYU Langone Grossman School of Medicine discussed a recent study she and colleagues conducted on new neurological disorders in patients with COVID-19.

The FDA told Xeris that it could advance diazepam directly into a phase 3 registration study for both pediatric and adult patients with epilepsy after reviewing phase 1b results.

Zosano plans to request a Type A meeting with the FDA to discuss strategies to address the FDA’s comments regarding the new drug application.